Euroopan unioni - suomi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Suomi - suomi - Fimea (Suomen lääkevirasto)

viatris oy - orphenadrine citrate - injektioneste, liuos - 30 mg/ml - orfenadriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

viatris oy - orphenadrine citrate - depottabletti - 100 mg - orfenadriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

viatris oy - glycopyrronium bromide - injektioneste, liuos - 0.2 mg/ml - glykopyrroniumbromidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

tillotts pharma gmbh - peppermint oil - enterokapseli, kova - menthae piperitae aetheroleum

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation orion pharma - peppermint oil - enterokapseli, pehmeä - menthae piperitae aetheroleum

Suomi - suomi - Fimea (Suomen lääkevirasto)

florealis ehf. - peppermint oil - enterokapseli, pehmeä - menthae piperitae aetheroleum

Suomi - suomi - Fimea (Suomen lääkevirasto)

dr. august wolff gmbh & co. kg arzneimittel - glycopyrronium bromide - emulsiovoide - 2,2 mg/pumpun käyttökerta - glykopyrronium

Euroopan unioni - suomi - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride succinate - ummetus - muut ummetuslääkkeet - resolor on tarkoitettu oireenmukaista hoitoa kroonisen ummetuksen aikuisilla, joille laksatiivit eivät tuo toivottua lievitystä.

Suomi - suomi - Fimea (Suomen lääkevirasto)

aktiebolaget draco - guaifenesinum,ephedrini hydrochloridum,cholini theophyllinas - tabletti - koliiniteofyllinaatti ja adrenergiset lääkeaineet